View Older Stories View More Recent Stories

May 6, 2025 08:00AM AbbVie to Present at the Bank of America Securities Healthcare Conference
May 1, 2025 05:00PM BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"
Apr 29, 2025 07:30AM AbbVie (ABBV) Reports RINVOQ Received FDA Approval for Giant Cell Arteritis (GCA)
Apr 29, 2025 07:30AM RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
Apr 25, 2025 07:43AM AbbVie Reports First-Quarter 2025 Financial Results
Apr 24, 2025 08:30AM AbbVie (ABBV) Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE
Apr 24, 2025 08:30AM AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
Apr 8, 2025 02:00AM AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
Mar 31, 2025 08:00AM AbbVie to Host First-Quarter 2025 Earnings Conference Call
Mar 26, 2025 08:30AM AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
Mar 24, 2025 04:02AM Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
Mar 15, 2025 08:00AM ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Mar 4, 2025 08:00AM AbbVie to Present at the Leerink Partners Global Healthcare Conference
Mar 3, 2025 01:11AM AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Feb 28, 2025 02:00AM AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
Feb 26, 2025 08:00AM AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
Feb 14, 2025 08:50AM AbbVie (ABBV) appoints CEO as Chairman of board
Feb 14, 2025 07:40AM AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Feb 13, 2025 11:57AM AbbVie Declares Quarterly Dividend
Feb 12, 2025 08:44AM AbbVie's Allergan Aesthetics set to launch three new training centers in U.S.
Feb 12, 2025 08:30AM Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Feb 12, 2025 07:31AM AbbVie (ABBV) and Xilio Therapeutics (XLO) Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Feb 12, 2025 07:30AM AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Feb 7, 2025 01:28PM AbbVie (ABBV) Announces FDA Approval of EMBLAVEO
Feb 7, 2025 01:27PM U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
Feb 6, 2025 08:05AM Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
Feb 5, 2025 09:00AM Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons
Jan 31, 2025 07:36AM AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
Jan 24, 2025 04:00AM Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
Jan 23, 2025 09:17AM AbbVie (ABBV) Completes Acquisition of Nimble Therapeutics
Jan 23, 2025 09:16AM AbbVie Completes Acquisition of Nimble Therapeutics
Jan 23, 2025 09:00AM AbbVie (ABBV) and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Jan 23, 2025 09:00AM AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Jan 13, 2025 09:05AM Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Jan 13, 2025 09:00AM AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Jan 13, 2025 08:31AM AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program
Jan 13, 2025 08:31AM AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Jan 9, 2025 08:00AM AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 3, 2025 08:00AM AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
Dec 26, 2024 09:00AM Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Dec 13, 2024 09:15AM AbbVie (ABBV) to Acquire Nimble Therapeutics
Dec 13, 2024 09:15AM AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Dec 11, 2024 09:15AM AbbVie (ABBV) Completes Acquisition of Aliada Therapeutics
Dec 11, 2024 09:15AM AbbVie Completes Acquisition of Aliada Therapeutics
Dec 9, 2024 12:02PM AbbVie (ABBV): Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-
Dec 9, 2024 12:00PM Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
Dec 9, 2024 08:02AM AbbVie (ABBV) Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Dec 9, 2024 08:00AM AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Dec 8, 2024 03:00PM AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
Dec 7, 2024 07:00PM Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
View More Recent Stories View Older Stories